Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lipella PharmaceuticalsLIPO -49.38% EV-to-EBIT is 0.27 as of Jul. 22, 2026. The stock has 1 warning sign investors should review. Among 372 Biotechnology companies, Lipella Pharmaceuticals ranks better than 89.52% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Lipella Pharmaceuticals's Enterprise Value for the quarter that ended in Sep. 2025 was $1.18 Mil.
Lipella Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.35 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lipella Pharmaceuticals EV-to-EBIT Related Terms
Lipella Pharmaceuticals EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Lipella Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lipella Pharmaceuticals EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lipella Pharmaceuticals's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Lipella Pharmaceuticals's EV-to-EBIT falls into.
Lipella Pharmaceuticals's current Enterprise Value is $-1.44 Mil.
Lipella Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.35 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lipella Pharmaceuticals (LIPO) has a EV-to-EBIT of 0.27 as of Jul. 22, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Lipella Pharmaceuticals and its competitors. According to the industry distribution chart, Lipella Pharmaceuticals ranks #39 out of 372 companies in the Biotechnology industry, placing it in the top 10.5%.
Is Lipella Pharmaceuticals' EV-to-EBIT too high?
Lipella Pharmaceuticals' current EV-to-EBIT is 0.27. The Biotechnology industry median EV-to-EBIT is 13.48. Lipella Pharmaceuticals' value of 0.27 is 98% below this industry median. Based on the distribution chart, Lipella Pharmaceuticals ranks #39 out of 372 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Lipella Pharmaceuticals' EV-to-EBIT compare to IOBTQ and WINT?
According to the Biotechnology industry distribution chart, Lipella Pharmaceuticals ranks #39 out of 372 companies for EV-to-EBIT. This places Lipella Pharmaceuticals in the top 11% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 13.48. Lipella Pharmaceuticals' value of 0.27 is 98% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 13.48, based on 372 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lipella Pharmaceuticals's current EV-to-EBIT of 0.27 is 98% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Lipella Pharmaceuticals and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 13.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lipella Pharmaceuticals's current EV-to-EBIT is 0.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lipella Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Lipella Pharmaceuticals (LIPO) is currently considered Possible Value Trap. The stock's GF Value™ is $8.74, compared to a current price of $0.03 — trading 99.6% below its estimated fair value. The current EV-to-EBIT is 0.27 and 98% below the Biotechnology industry median of 13.48. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Lipella Pharmaceuticals (LIPO), the current EV-to-EBIT is 0.27 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410, which can be helpful in the treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LIPO has been successfully added to your 
